Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $55,862 - $91,016
-3,100 Reduced 7.18%
40,100 $1.11 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $465,696 - $1.1 Million
43,200 New
43,200 $993,000
Q1 2022

May 16, 2022

BUY
$23.34 - $36.08 $72,354 - $111,848
3,100 Added 23.48%
16,300 $386,000
Q4 2021

Feb 14, 2022

BUY
$17.63 - $37.1 $232,716 - $489,720
13,200 New
13,200 $451,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.